Loading…
Reported covered position: Chief of Staff, Rep. Ruiz; Chief of Staff, Rep. Speier; Dep. Chief of Staff, Rep. Udall; Special Assistant, Sen. Bayh; Confidential Assistant, USDA; Assistant to Special Assistant to the President, White House Office of Political Affairs
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Speeding Therapy Access Today Act of 2021
Client: INOVIO PHARMACEUTICALS, INC. · Firm: INOVIO PHARMACEUTICALS, INC.
Issues related to COVID-19 research and development, vaccine distribution and manufacturing; Issues related to Oncology; Next Generation COVID-19 vaccines and boosters; Medicare Part B and HPV; Issues related to BARDA/ASPR and manufacturing of COVID-19 vaccines and boosters; Prescription Drug User Fee Act (PDUFA); Medical Device User Fees Amendment (MDUFA IV); ARPA-H Act, H.R 5585; Accelerated Approval Integrity Act of 2022, H.R. 6963; Speeding Therapy Access Today (STAT) Act, H.R. 1730; Prevent Pandemic Act, S. 3799
Consolidated Appropriations Act, 2023
Client: INOVIO PHARMACEUTICALS, INC. · Firm: INOVIO PHARMACEUTICALS, INC.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
INOVIO PHARMACEUTICALS, INC. via INOVIO PHARMACEUTICALS, INC.
2023 · third_quarter · Q3
Issues related to the Pandemic and All Hazards Preparedness Act (PAHPA) reauthorization; Next Generation COVID-19 vaccines and boosters; Issues related to Accelerated Approval reforms and accelerated approval pathway at FDA and decentralized trials; Issues related to Recurrent Respiratory Papillomatosis (RRP), an HPV associated disease; DNA Medicines Platform Technology awareness; Issues related to medical devices and cybersecurity issues; Issues related to Transitional Coverages of Emerging Technologies (TCET) and medical devices; Issues related to funding for Advanced Research Projects Agency for Health
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
Source: Senate LDA
Issues related to COVID-19 research and development, vaccine distribution and manufacturing; Next Generation COVID-19 vaccines and boosters; Issues related to ASPR/BARDA and manufacturing of COVID-10 vaccines and boosters; Issues related to Oncology and HPV cancers; Continuing Resolution (CR), H.R. 6833, the Continuing Resolution and Ukraine Supplemental Appropriations Act; FY2023 Omnibus Appropriations Act, H.R. 2617; Issues related to the Prescription Drug User Fee Act (PDUFA); Issues related to the Medical Device User Fees Amendment (MDUFA IV); ARPA-H Act, H.R 5585; Accelerated Approval Integrity Act of 2022, H.R. 6963; Prevent Pandemic Act, S. 3799; DNA Medicines awareness
Issues related to COVID-19 research and development, vaccine distribution and manufacturing; Next Generation COVID-19 vaccines and boosters; Issues related to ASPR/BARDA and manufacturing of COVID-10 vaccines and boosters; Issues related to Oncology and HPV cancers; Continuing Resolution (CR), H.R. 6833, the Continuing Resolution and Ukraine Supplemental Appropriations Act; FY2023 Omnibus Appropriations Act, H.R. 2617; Issues related to the Prescription Drug User Fee Act (PDUFA); Issues related to the Medical Device User Fees Amendment (MDUFA IV); ARPA-H Act, H.R 5585; Accelerated Approval Integrity Act of 2022, H.R. 6963; Prevent Pandemic Act, S. 3799; DNA Medicines awareness
Issues related to COVID-19 research and development, vaccine distribution and manufacturing; Issues related to Oncology and HPV cancers; Next Generation COVID-19 vaccines and boosters; Issues related to BARDA/ASPR and manufacturing of COVID-19 vaccines and boosters; Continuing Resolution (CR), H.R. 6833, the Continuing Resolution and Ukraine Supplemental Appropriations Act; Prescription Drug User Fee Act (PDUFA); Medical Device User Fees Amendment (MDUFA IV); ARPA-H Act, H.R 5585; Accelerated Approval Integrity Act of 2022, H.R. 6963; Prevent Pandemic Act, S. 3799; DNA Medicines awareness.
Issues related to COVID-19 research and development, vaccine distribution and manufacturing; Issues related to Oncology; Next Generation COVID-19 vaccines and boosters; Medicare Part B and HPV; Issues related to BARDA/ASPR and manufacturing of COVID-19 vaccines and boosters; Prescription Drug User Fee Act (PDUFA); Medical Device User Fees Amendment (MDUFA IV); ARPA-H Act, H.R 5585; Accelerated Approval Integrity Act of 2022, H.R. 6963; Speeding Therapy Access Today (STAT) Act, H.R. 1730; Prevent Pandemic Act, S. 3799
Issues related to COVID-19 research and development, vaccine distribution and manufacturing; Issues related to Oncology Next Generation COVID-19 vaccines; Medicare Part B and HPV; Orphan Drug Act of 1983 Orphan Drug Tax Credit - The Build Back Better Act, H.R. 5673; Accelerated Approval Integrity Act of 2022, H.R. 6963; Prescription Drug User Fee Act (PDUFA); Medical Device User Fees Amendments (MDUFA IV); Prevent Pandemics Act, S. 3799; Cures 2.0, H.R. 6000; Issues related to BARDA/ASPR and manufacturing of COVID-19 vaccines and therapies TRIPS Waiver for COVID-19 vaccines and therapies; Outreach to Colombian Congressional Caucus on COVID-19
Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
Client: INOVIO PHARMACEUTICALS, INC. · Firm: INOVIO PHARMACEUTICALS, INC.
Issues related to COVID-19 research and development, vaccine distribution and manufacturing; Next Generation COVID-19 vaccines and boosters; Issues related to ASPR/BARDA and manufacturing of COVID-10 vaccines and boosters; Issues related to Oncology and HPV cancers; Continuing Resolution (CR), H.R. 6833, the Continuing Resolution and Ukraine Supplemental Appropriations Act; FY2023 Omnibus Appropriations Act, H.R. 2617; Issues related to the Prescription Drug User Fee Act (PDUFA); Issues related to the Medical Device User Fees Amendment (MDUFA IV); ARPA-H Act, H.R 5585; Accelerated Approval Integrity Act of 2022, H.R. 6963; Prevent Pandemic Act, S. 3799; DNA Medicines awareness
Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
Client: INOVIO PHARMACEUTICALS, INC. · Firm: INOVIO PHARMACEUTICALS, INC.
Issues related to COVID-19 research and development, vaccine distribution and manufacturing; Issues related to Oncology and HPV cancers; Next Generation COVID-19 vaccines and boosters; Issues related to BARDA/ASPR and manufacturing of COVID-19 vaccines and boosters; Continuing Resolution (CR), H.R. 6833, the Continuing Resolution and Ukraine Supplemental Appropriations Act; Prescription Drug User Fee Act (PDUFA); Medical Device User Fees Amendment (MDUFA IV); ARPA-H Act, H.R 5585; Accelerated Approval Integrity Act of 2022, H.R. 6963; Prevent Pandemic Act, S. 3799; DNA Medicines awareness.
Accelerated Approval Integrity Act of 2022
Client: INOVIO PHARMACEUTICALS, INC. · Firm: INOVIO PHARMACEUTICALS, INC.
Issues related to COVID-19 research and development, vaccine distribution and manufacturing; Next Generation COVID-19 vaccines and boosters; Issues related to ASPR/BARDA and manufacturing of COVID-10 vaccines and boosters; Issues related to Oncology and HPV cancers; Continuing Resolution (CR), H.R. 6833, the Continuing Resolution and Ukraine Supplemental Appropriations Act; FY2023 Omnibus Appropriations Act, H.R. 2617; Issues related to the Prescription Drug User Fee Act (PDUFA); Issues related to the Medical Device User Fees Amendment (MDUFA IV); ARPA-H Act, H.R 5585; Accelerated Approval Integrity Act of 2022, H.R. 6963; Prevent Pandemic Act, S. 3799; DNA Medicines awareness
Accelerated Approval Integrity Act of 2022
Client: INOVIO PHARMACEUTICALS, INC. · Firm: INOVIO PHARMACEUTICALS, INC.
Issues related to COVID-19 research and development, vaccine distribution and manufacturing; Issues related to Oncology and HPV cancers; Next Generation COVID-19 vaccines and boosters; Issues related to BARDA/ASPR and manufacturing of COVID-19 vaccines and boosters; Continuing Resolution (CR), H.R. 6833, the Continuing Resolution and Ukraine Supplemental Appropriations Act; Prescription Drug User Fee Act (PDUFA); Medical Device User Fees Amendment (MDUFA IV); ARPA-H Act, H.R 5585; Accelerated Approval Integrity Act of 2022, H.R. 6963; Prevent Pandemic Act, S. 3799; DNA Medicines awareness.
Accelerated Approval Integrity Act of 2022
Client: INOVIO PHARMACEUTICALS, INC. · Firm: INOVIO PHARMACEUTICALS, INC.
Issues related to COVID-19 research and development, vaccine distribution and manufacturing; Issues related to Oncology Next Generation COVID-19 vaccines; Medicare Part B and HPV; Orphan Drug Act of 1983 Orphan Drug Tax Credit - The Build Back Better Act, H.R. 5673; Accelerated Approval Integrity Act of 2022, H.R. 6963; Prescription Drug User Fee Act (PDUFA); Medical Device User Fees Amendments (MDUFA IV); Prevent Pandemics Act, S. 3799; Cures 2.0, H.R. 6000; Issues related to BARDA/ASPR and manufacturing of COVID-19 vaccines and therapies TRIPS Waiver for COVID-19 vaccines and therapies; Outreach to Colombian Congressional Caucus on COVID-19
Accelerated Approval Integrity Act of 2022
Client: INOVIO PHARMACEUTICALS, INC. · Firm: INOVIO PHARMACEUTICALS, INC.
Issues related to COVID-19 research and development, vaccine distribution and manufacturing; Issues related to Oncology; Next Generation COVID-19 vaccines and boosters; Medicare Part B and HPV; Issues related to BARDA/ASPR and manufacturing of COVID-19 vaccines and boosters; Prescription Drug User Fee Act (PDUFA); Medical Device User Fees Amendment (MDUFA IV); ARPA-H Act, H.R 5585; Accelerated Approval Integrity Act of 2022, H.R. 6963; Speeding Therapy Access Today (STAT) Act, H.R. 1730; Prevent Pandemic Act, S. 3799
COVID Supplemental Appropriations Act, 2022
Client: INOVIO PHARMACEUTICALS, INC. · Firm: INOVIO PHARMACEUTICALS, INC.
COVID-19 Supplemental Appropriations Act of 2022, H.R. 7007, AG/FDA FY2023 appropriations, State, Foreign Ops FY2023 appropriations; LHHS FY2023 appropriations
PREVENT Pandemics Act
Client: INOVIO PHARMACEUTICALS, INC. · Firm: INOVIO PHARMACEUTICALS, INC.
Issues related to COVID-19 research and development, vaccine distribution and manufacturing; Next Generation COVID-19 vaccines and boosters; Issues related to ASPR/BARDA and manufacturing of COVID-10 vaccines and boosters; Issues related to Oncology and HPV cancers; Continuing Resolution (CR), H.R. 6833, the Continuing Resolution and Ukraine Supplemental Appropriations Act; FY2023 Omnibus Appropriations Act, H.R. 2617; Issues related to the Prescription Drug User Fee Act (PDUFA); Issues related to the Medical Device User Fees Amendment (MDUFA IV); ARPA-H Act, H.R 5585; Accelerated Approval Integrity Act of 2022, H.R. 6963; Prevent Pandemic Act, S. 3799; DNA Medicines awareness
PREVENT Pandemics Act
Client: INOVIO PHARMACEUTICALS, INC. · Firm: INOVIO PHARMACEUTICALS, INC.
Issues related to COVID-19 research and development, vaccine distribution and manufacturing; Issues related to Oncology and HPV cancers; Next Generation COVID-19 vaccines and boosters; Issues related to BARDA/ASPR and manufacturing of COVID-19 vaccines and boosters; Continuing Resolution (CR), H.R. 6833, the Continuing Resolution and Ukraine Supplemental Appropriations Act; Prescription Drug User Fee Act (PDUFA); Medical Device User Fees Amendment (MDUFA IV); ARPA-H Act, H.R 5585; Accelerated Approval Integrity Act of 2022, H.R. 6963; Prevent Pandemic Act, S. 3799; DNA Medicines awareness.
PREVENT Pandemics Act
Client: INOVIO PHARMACEUTICALS, INC. · Firm: INOVIO PHARMACEUTICALS, INC.
Issues related to COVID-19 research and development, vaccine distribution and manufacturing; Issues related to Oncology Next Generation COVID-19 vaccines; Medicare Part B and HPV; Orphan Drug Act of 1983 Orphan Drug Tax Credit - The Build Back Better Act, H.R. 5673; Accelerated Approval Integrity Act of 2022, H.R. 6963; Prescription Drug User Fee Act (PDUFA); Medical Device User Fees Amendments (MDUFA IV); Prevent Pandemics Act, S. 3799; Cures 2.0, H.R. 6000; Issues related to BARDA/ASPR and manufacturing of COVID-19 vaccines and therapies TRIPS Waiver for COVID-19 vaccines and therapies; Outreach to Colombian Congressional Caucus on COVID-19
PREVENT Pandemics Act
Client: INOVIO PHARMACEUTICALS, INC. · Firm: INOVIO PHARMACEUTICALS, INC.
Issues related to COVID-19 research and development, vaccine distribution and manufacturing; Issues related to Oncology; Next Generation COVID-19 vaccines and boosters; Medicare Part B and HPV; Issues related to BARDA/ASPR and manufacturing of COVID-19 vaccines and boosters; Prescription Drug User Fee Act (PDUFA); Medical Device User Fees Amendment (MDUFA IV); ARPA-H Act, H.R 5585; Accelerated Approval Integrity Act of 2022, H.R. 6963; Speeding Therapy Access Today (STAT) Act, H.R. 1730; Prevent Pandemic Act, S. 3799
2023 · second_quarter · Q2
Issues related to Recurrent Respiratory Papillomatosis (RRP), an HPV associated disease; Issues related to the Orphan Drug Act and orphan drug destination; Issues related to the Orphan Drug Tax Credit; Issues related to Accelerated Approval reforms and accelerated approval pathway at FDA and decentralized trials; Issues related to CMS IRA implementation and small biotech exemption; Issues related to the Pandemic and All Hazards Preparedness Act (PAHPA) reauthorization; Next Generation COVID-19 vaccines and boosters; Issues related to ASPR/BARDA and manufacturing of pan-coronavirus vaccines and boosters; Issues related to Oncology and HPV cancers and other associated diseases; Issues related to medical devices and cybersecurity issues; Issues related to Transitional Coverages of Emerging Technologies (TCET) and medical devices; Issues related to FY2024 Labor, Health and Human Services and Education Annual Appropriations; DNA Medicines Platform Technology awareness
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
INOVIO PHARMACEUTICALS, INC. via INOVIO PHARMACEUTICALS, INC.
2023 · first_quarter · Q1
Issues related to Recurrent Respiratory Papillomatosis (RRP), an HPV associated disease; Issues related to the Orphan Drug Act and orphan drug destination; Issues related to the Orphan Drug Tax Credit; Issues related to Accelerated Approval reforms and accelerated approval pathway at FDA; Issues related to CMS IRA implementation and small biotech exemption; Issues related to the Pandemic and All Hazards Preparedness Act (PAHPA) reauthorization; Next Generation COVID-19 vaccines and boosters; Issues related to ASPR/BARDA and manufacturing of pan-coronavirus vaccines and boosters; Issues related to Oncology and HPV cancers and other associated diseases; DNA Medicines Platform Technology awareness
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
INOVIO PHARMACEUTICALS, INC. via INOVIO PHARMACEUTICALS, INC.
2022 · fourth_quarter · Q4
Issues related to COVID-19 research and development, vaccine distribution and manufacturing; Next Generation COVID-19 vaccines and boosters; Issues related to ASPR/BARDA and manufacturing of COVID-10 vaccines and boosters; Issues related to Oncology and HPV cancers; Continuing Resolution (CR), H.R. 6833, the Continuing Resolution and Ukraine Supplemental Appropriations Act; FY2023 Omnibus Appropriations Act, H.R. 2617; Issues related to the Prescription Drug User Fee Act (PDUFA); Issues related to the Medical Device User Fees Amendment (MDUFA IV); ARPA-H Act, H.R 5585; Accelerated Approval Integrity Act of 2022, H.R. 6963; Prevent Pandemic Act, S. 3799; DNA Medicines awareness
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
INOVIO PHARMACEUTICALS, INC. via INOVIO PHARMACEUTICALS, INC.
2022 · third_quarter · Q3
Issues related to COVID-19 research and development, vaccine distribution and manufacturing; Issues related to Oncology and HPV cancers; Next Generation COVID-19 vaccines and boosters; Issues related to BARDA/ASPR and manufacturing of COVID-19 vaccines and boosters; Continuing Resolution (CR), H.R. 6833, the Continuing Resolution and Ukraine Supplemental Appropriations Act; Prescription Drug User Fee Act (PDUFA); Medical Device User Fees Amendment (MDUFA IV); ARPA-H Act, H.R 5585; Accelerated Approval Integrity Act of 2022, H.R. 6963; Prevent Pandemic Act, S. 3799; DNA Medicines awareness.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
INOVIO PHARMACEUTICALS, INC. via INOVIO PHARMACEUTICALS, INC.
2022 · second_quarter · Q2
FY 2023 appropriations - LHHS, AG/FDA, State, Foreign Ops
Issues related to COVID-19 research and development, vaccine distribution and manufacturing; Issues related to Oncology; Next Generation COVID-19 vaccines and boosters; Medicare Part B and HPV; Issues related to BARDA/ASPR and manufacturing of COVID-19 vaccines and boosters; Prescription Drug User Fee Act (PDUFA); Medical Device User Fees Amendment (MDUFA IV); ARPA-H Act, H.R 5585; Accelerated Approval Integrity Act of 2022, H.R. 6963; Speeding Therapy Access Today (STAT) Act, H.R. 1730; Prevent Pandemic Act, S. 3799
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), White House Office
INOVIO PHARMACEUTICALS, INC. via INOVIO PHARMACEUTICALS, INC.
2022 · first_quarter · Q1
COVID-19 Supplemental Appropriations Act of 2022, H.R. 7007, AG/FDA FY2023 appropriations, State, Foreign Ops FY2023 appropriations; LHHS FY2023 appropriations
Issues related to COVID-19 research and development, vaccine distribution and manufacturing; Issues related to Oncology Next Generation COVID-19 vaccines; Medicare Part B and HPV; Orphan Drug Act of 1983 Orphan Drug Tax Credit - The Build Back Better Act, H.R. 5673; Accelerated Approval Integrity Act of 2022, H.R. 6963; Prescription Drug User Fee Act (PDUFA); Medical Device User Fees Amendments (MDUFA IV); Prevent Pandemics Act, S. 3799; Cures 2.0, H.R. 6000; Issues related to BARDA/ASPR and manufacturing of COVID-19 vaccines and therapies TRIPS Waiver for COVID-19 vaccines and therapies; Outreach to Colombian Congressional Caucus on COVID-19
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), White House Office
INOVIO PHARMACEUTICALS, INC. via INOVIO PHARMACEUTICALS, INC.
2022 · first_quarter · RR
Issues related to COVID-19 and other infectious diseases; HPV cancer and other diseases and Oncology/Cancer (Pipeline); funding for HHS agencies such as NIH, NCI, FDA and Global Health Security within the State Department and USAID.
Issues related to COVID-19 and other infectious diseases; HPV cancer and other diseases and Oncology/Cancer (Pipeline); funding for HHS agencies such as NIH, NCI, FDA and Global Health Security within the State Department and USAID.
Issues related to COVID-19 and other infectious diseases; HPV cancer and other diseases and Oncology/Cancer (Pipeline); funding for HHS agencies such as NIH, NCI, FDA and Global Health Security within the State Department and USAID.